Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. HONA

Go back to Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
(NASDAQ: PRAX) Delayed: 351.81 -3.34 (0.94%)
Previous Close $355.15    52 Week High $ 
Open $352.99    52 Week Low $ 
Day High $357.50    P/E N/A 
Day Low $349.82    EPS $ 
Volume 175,356